Welcome to LookChem.com Sign In|Join Free
  • or
(S)-2-pyrrolidin-1-yl-methyl-pyrrolidine-1-carboxylic acid [4-(4,4,5,5-tetramethyl-[1,3,2]dioxaborolan-2-yl)-phenyl]-amide is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

867256-62-0

Post Buying Request

867256-62-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

867256-62-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 867256-62-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,6,7,2,5 and 6 respectively; the second part has 2 digits, 6 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 867256-62:
(8*8)+(7*6)+(6*7)+(5*2)+(4*5)+(3*6)+(2*6)+(1*2)=210
210 % 10 = 0
So 867256-62-0 is a valid CAS Registry Number.

867256-62-0Downstream Products

867256-62-0Relevant academic research and scientific papers

Synthesis and structure-activity relationships of 1,2,3,4-tetrahydropyrido[2,3-b]pyrazines as potent and selective inhibitors of the anaplastic lymphoma kinase

Milkiewicz, Karen L.,Weinberg, Linda R.,Albom, Mark S.,Angeles, Thelma S.,Cheng, Mangeng,Ghose, Arup K.,Roemmele, Renee C.,Theroff, Jay P.,Underiner, Ted L.,Zificsak, Craig A.,Dorsey, Bruce D.

experimental part, p. 4351 - 4362 (2010/09/12)

Dysregulation of the anaplastic lymphoma kinase (ALK) is implicated in a variety of cancers. A series of tetrahydropyrido[2,3-b]pyrazines was constructed as ring-constrained analogs of a known aminopyridine kinase scaffold. Chemistry was developed to rapidly elaborate the SAR, structural elements impacting ALK inhibitory activity were exploited, and kinase selective analogs were identified that inhibit ALK with IC50 values ~10 nM (enzyme) and ~150 nM (cell).

HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES

-

Page/Page column 22, (2010/03/31)

The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases

HISTAMINE H3 RECEPTOR AGENTS, PREPARATION AND THERAPEUTIC USES

-

Page/Page column 55, (2008/06/13)

The present invention discloses novel compounds of Formula (I) or pharmaceutically acceptable salts thereof, which have histamine-H3 receptor antagonist or inverse agonist activity, as well as methods for preparing such compounds. In another embodiment, the invention discloses pharmaceutical compositions comprising compounds of Formula (I) as well as methods of using them to treat obesity, cognitive deficiencies, narcolepsy, and other histamine H3 receptor-related diseases

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 867256-62-0